보고서 요약(국문)

개요
전 세계 비강 폴립 치료제 시장은 2022년 XX백만 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) XX%로 성장하여 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
비강 폴립은 얼굴 뼈 또는 코 안의 빈 공간인 부비동 내부에 발생하는 통증 없는 혹입니다. 비강 폴립은 암이 아닙니다. 작은 비강 폴립은 아무런 증상을 나타내지 않을 수 있습니다. 여러 개의 비강 폴립이 모여 있거나 크기가 커지면 코를 막아 감염, 호흡 곤란, 후각 상실을 유발할 수 있습니다. 누구나 비강 폴립이 발생할 수 있지만, 젊은 성인과 중년 성인에게 더 흔합니다.
약물 치료로 비강 폴립을 줄이거나 없앨 수 있지만, 완전히 제거하려면 수술이 필요할 수 있습니다. 비강 폴립은 치료 후에도 재발하는 경우가 많습니다. 비강 폴립증은 12주 이상 지속되는 부비동 및 코의 부종과 자극을 동반하는 질환입니다. 이러한 증상은 염증으로도 알려져 있습니다. 만성 부비동염은 비강 내부에서 발생하는 문제이지만, 비강 폴립증이 반드시 만성 부비동염을 의미하는 것은 아닙니다.
시장 동향: 성장 동력 및 제약 요인
기술 발전의 증가
비강 폴립증의 진단 및 관리는 최소 침습 수술 기법, 내시경 치료, 영상 기술 등의 의료 기술 발전으로 개선되었습니다. 이러한 발전은 환자의 치료 결과를 향상시키고 시장 확대를 촉진합니다. 예를 들어, 옵티노스는 2021년 6월 2일 국제 알레르기 및 비과학 포럼에서 발표한 새로운 단계별 치료 알고리즘인 "비강 폴립증을 동반한 만성 비부비동염 관리를 위한 단계별 치료 알고리즘에 대한 다학제적 합의"에서 비강 폴립증 환자 치료에 플루티카손 흡입 전달 시스템(EDS-FLU)을 권장한다고 밝혔습니다.

EDS-FLU는 기존의 비강 스테로이드 초기 치료와 수술 또는 생물학적 제제 치료로의 전환 사이의 중간 단계로 권장됩니다. 또한, 특히 선진국에서 의료비가 상승함에 따라 비강 폴립증 치료와 같은 의료 서비스 및 치료에 대한 투자가 증가하고 있습니다.
이러한 재정적 지원 덕분에 새로운 치료법이 개발, 연구 및 도입되고 있습니다. 비강 폴립증은 전 세계적으로 발생 빈도가 증가하고 있는 흔한 질환입니다. 비강 폴립증 환자 수는 대기 오염 증가, 알레르겐 노출 증가, 생활 방식 변화 등의 요인으로 인해 증가하고 있습니다.
시장 동향: 제약 요인
비강 폴립증 시장은 여러 가지 원인으로 인해 성장에 제약을 받을 수 있습니다. 이 질환에 대한 의약품 및 치료법의 개발, 도입 및 마케팅은 여러 장애물에 직면할 수 있습니다. 예를 들어, 비강 폴립증 치료, 특히 시술 및 지속적인 약물 치료는 비용이 많이 들 수 있습니다.

환자들은 특히 보험 선택권과 의료 자원이 부족한 지역에서 이러한 비용이 치료 접근성에 상당한 장벽이 될 수 있음을 알게 될 것입니다. 코르티코스테로이드와 면역억제제는 비강 폴립증 치료에 사용되는 두 가지 약물이지만, 부작용이 있을 수 있습니다. 환자와 의사는 안전 문제 및 발생 가능한 부작용 때문에 특정 치료법을 선택하지 않을 수도 있습니다.
보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
전 세계 비강 폴립증 시장은 질병 유형, 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
질병 유형 세그먼트에서 코르티코스테로이드 부문은 비강 폴립증 시장의 약 41.7%를 차지했습니다.
코르티코스테로이드 치료에 대한 수요 증가와 주사, 비강 스프레이, 점적액 등 환자의 필요에 따라 다양한 제형으로 제공됨에 따라 코르티코스테로이드 부문은 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 또한, 여러 코르티코스테로이드 제제가 비강 폴립증을 축소시킬 수 있는 국소 제제 및 에어로졸 형태로 쉽게 구할 수 있습니다. 더불어, 제품 승인 증가 또한 해당 부문의 빠른 성장에 기여하고 있습니다.
예를 들어, 글락소스미스클라인(GSK)에 따르면, 2021년 7월 29일 미국 식품의약국(FDA)은 인터루킨-5(IL-5)를 차단하는 단클론 항체인 누칼라(메폴리주맙)를 만성 비부비동염 및 비강 폴립증(CRSwNP) 환자 치료제로 승인했습니다. 메폴리주맙의 새로운 적응증은 비강 코르티코스테로이드에 적절히 반응하지 않는 18세 이상 성인 CRSwNP 환자의 추가 유지 치료입니다. 이처럼 모든 요인이 해당 부문의 성장을 촉진하고 있습니다.

지리적 분석
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
전반적인 비강 폴립증 시장은 예측 기간 동안 북미가 주도할 것으로 예상됩니다. 이는 주로 다양한 악성 종양과 천식, 부비동염 등의 알레르기 질환 유병률 증가에 기인합니다. 미국의 연구 활동과 더불어 규제 기관의 승인 증가는 비강 폴립증 시장 확대를 촉진할 것으로 기대됩니다.
예를 들어, 노바티스에 따르면 2020년 12월 1일 미국 식품의약국(FDA)은 비강 코르티코스테로이드에 적절히 반응하지 않는 18세 이상 성인 비강 폴립증 환자의 유지 치료를 위한 졸레어(오말리주맙)의 추가 생물학적 제제 허가 신청(sBLA)을 승인했습니다.

또한, 알레르기 질환의 빈도와 제약 산업의 지속적인 최근 확장으로 인해 아시아 태평양 지역은 예측 기간 동안 가장 빠른 속도로 성장할 것으로 예상됩니다. 중국은 인구가 많고 의료 분야에 대한 정부의 적극적인 활동으로 인해 아시아 태평양 지역에서 중요한 위치를 차지하고 있습니다. 향후 임상 시험을 통해 지역 시장 확장은 더욱 가속화될 것입니다.
COVID-19 영향 분석
후각 상실과 같은 비강 폴립증 관련 COVID-19 증상으로 인해 COVID-19 팬데믹은 전 세계 비강 폴립증 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어, 만성 비부비동염은 비강 점막의 지속적인 염증을 특징으로 하는 질환이며, 2022년 6월 Elsevier 저널에 발표된 정보에 따르면 표현형적으로 비강 폴립증을 동반한 만성 비부비동염으로 분류됩니다.
만성 비부비동염 환자의 56~78%가 기능 장애를 경험합니다. 코로나19의 흔한 초기 증상 중 하나는 코막힘 없이 후각을 잃는 것입니다. 코로나19 질환과 만성 비부비동염의 증상은 거의 동일하며, 후각 상실도 그중 하나입니다. 이로 인해 비강 폴립증 치료제에 대한 수요가 증가했으며, 이는 전 세계적으로 해당 의약품 시장의 성장을 촉진할 것으로 예상됩니다.
시장 세분화
질병 유형별
• 양측 사골 폴립
• 상악동 폴립
약물 계열별
• 비강 코르티코스테로이드
o 플루티카손
o 모메타손
o 부데소니드
o 베클로메타손
o 기타
• 경구 코르티코스테로이드
o 프레드니손
o 프레드니솔론
• 항히스타민제
o 세티리진
o 로라타딘
o 펙소페나딘
o 기타
• 류코트리엔 조절제
o 몬테루카스트
o 자피를루카스트
• 기타
투여 경로별
• 경구
• 주사
• 비강
• 기타
유통 채널별
• 병원 약국
• 온라인 약국
• 소매 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 지역 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Mylan N.V., Intersect ENT Inc, GlaxoSmithKline PLC, Lupin, Sanofi S.A, Sun Pharmaceutical Industries Ltd, Anant Pharmaceuticals Pvt. Ltd., OptiNose US, Teva Pharmaceutical Industries Ltd., Merck & Co Inc 등이 있습니다.
주요 개발 사항
• 2020년 8월 6일, Novartis는 INC 요법으로 충분한 질병 조절 효과를 얻지 못하는 중증 만성 비부비동염 및 비강 폴립증(CRSwNP)을 앓는 18세 이상 성인 환자의 치료를 위해 유럽 위원회(EC)가 Xolair(omalizumab)를 비강 코르티코스테로이드(INC) 병용 요법으로 승인했다고 발표했습니다.

보고서 구매 이유

• 질병 유형, 약물 종류, 투여 경로, 유통 채널 및 지역별 글로벌 비강 폴립증 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴하기 위해

• 모든 세그먼트를 포함한 비강 폴립증 시장 수준의 다양한 데이터가 담긴 엑셀 시트 제공

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서 제공

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 엑셀 파일 제공

글로벌 비강 폴립증 시장 보고서는 약 69개의 표, 69개의 그림, 187페이지 분량으로 구성됩니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Nasal Polyposis Drugs Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Nasal polyposis are painless growths inside the sinuses, which are the hollow spaces inside the face's bones, or the nose. Nor are nasal polyposis cancer. Small nasal polyposis may not show any symptoms at all. Nasal polyposis in groups or larger growths can block the nose. They may result in infections, difficulty breathing, and loss of smell. Everyone can develop nasal polyposis. But young and middle-aged adults are more likely to develop these nasal polyposis.
Medications frequently reduce or eliminate nasal polyposis. But to get rid of them might require surgery. Nasal polyposis frequently recur even after being treated. Nasal polyposis are associated with sinus and nose swelling and irritation that lasts longer than 12 weeks. This condition is also known as inflammation. Chronic sinusitis is the issue going on inside. But nasal polyposis do not indicate a need for chronic sinusitis.
Market Dynamics: Drivers and Restraints
The rise of technological advancements
The diagnosis and management of nasal polyposis had been improved by developments in medical technology, such as less invasive surgical techniques, endoscopic treatments, and imaging technologies. These developments enhance patient outcomes while driving market expansion. For instance, Optinose stated on June 2, 2021, that the International Forum of Allergy & Rhinology's publication of a new stepped-care treatment algorithm, "Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyposis," recommends Exhalation Delivery System-fluticasone (EDS-FLU) for the treatment of patients with nasal polyposis.
EDS-FLU is also advised as a step between initial treatment with conventional intranasal steroids and treatment escalation with surgery or biologic medications. Additionally, the increasing cost of healthcare, particularly in industrialised nations, enables increased investment in healthcare services and treatments, such as those for nasal polyposis.
New treatments are developed, researched, and adopted as a result of this financial backing. Nasal polyposis is a widespread disorder with a rising frequency around the globe. The number of persons affected by nasal polyposis is increasing, in part due to factors like rising pollution levels, higher allergen exposure, and changing lifestyles.
Market Dynamics: Restraint
The nasal polyposis market may experience limitations on expansion due to various causes. The creation, adoption, and marketing of medicines and treatments for this ailment may be hampered by several obstacles. For instance, nasal polyposis treatments can be expensive, particularly when it comes to procedures and ongoing drugs.
Patients may find this expense to be a substantial barrier to access, especially in areas with few insurance options and healthcare resources. Corticosteroids and immunosuppressive medications are two more treatments for nasal polyposis that may have unfavourable side effects. Patients and doctors may choose not to pursue particular treatment options due to safety concerns and possible adverse effects.
For more details of the report, Request for sample
Segment Analysis
The global nasal polyposis marketis segmented based on disease type, drug class, route of administration, distribution channel and region.
The corticosteroid segment from the disease type segment accounted for approximately 41.7% of nasal polyposis market
Due to the rising demand for corticosteroid treatment and its availability in a variety of dose forms, including injections, intranasal sprays, and drops depending on the patient's needs, the corticosteroid segment is expected to retain the largest market share. Additionally, several corticosteroids are readily available as topical preparations and aerosols that might shrink nasal polyposis. Additionally, the increase in product approvals also contributes to the segment's faster expansion.
For instance, July 29, 2021, US Food and Drug Administration (FDA) had approved Nucala (mepolizumab), a monoclonal antibody that blocks interleukin-5 (IL-5), as a treatment for people with chronic rhinosinusitis with nasal polyposis (CRSwNP), according to GlaxoSmithKline plc (GSK). The add-on maintenance treatment of CRSwNP in adult patients, 18 years of age and older, who have not responded adequately to nasal corticosteroids is the new indication for mepolizumab. Thus, all of those factors boost segment expansion.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
The nasal polyposis market as a whole is anticipated to be dominated by North America for the forecast period. This is mainly due to the rising prevalence of different malignancies and allergy diseases like asthma, sinusitis, and others. Research efforts in the United States, in addition to more regulatory agency approvals, are expected to fuel the expansion of the nasal polyposis market.
For instance, on December 01, 2020, according to Novartis, the US Food and Drug Administration (FDA) had approved the company's supplemental Biologics Licence Application (sBLA) for Xolair (omalizumab) for the maintenance treatment of nasal polyposis in adult patients, 18 years of age and older, who have not responded adequately to nasal corticosteroids.
Additionally, due to the frequency of allergic diseases and the pharmaceutical industry's consistent recent expansion, Asia Pacific is expected to increase at the most rapid pace during the forecast period. China is important in the region of Asia-Pacific because of its large population and extensive government activities in the healthcare field. Regional market expansion will be further boosted by further trials.
COVID-19 Impact Analysis
Due to COVID-19 symptoms associated with nasal polyposis, such as loss of smell, the COVID-19 pandemic is anticipated to propel growth of the global market for nasal polyposis. For instance, chronic rhinosinusitis is a condition marked by persistent inflammation of the sinonasal mucosa and is phenotypically categorised as chronic rhinosinusitis with nasal polyposis, according to information published in the Elsevier Journal in June 2022.
Between 56 and 78% of people with chronic rhinosinusitis experience impairment. One of the frequent early symptoms of COVID-19 is olfactory loss without nasal congestion. Nearly all of the symptoms of COVID-19 illness and chronic rhinosinusitis are the same, including loss of smell. This has led to an increase in the demand for medications used to treat nasal polyposis, which is anticipated to fuel the expansion of the market for those medications worldwide.
Market Segmentation
By Disease Type
• Bilateral ethmoidal polyp
• Antrochoanal Polyp
By Drug Class
• Nasal Corticosteroids
o Fluticasone
o Mometasone
o Budesonide
o Beclomethasone
o Others
• Oral Corticosteroids
o Prednisone
o Prednisolone
• Antihistamines
o Cetirizine
o Loratadine
o Fexofenadine
o Others
• Leukotriene Modifiers
o Montelukast
o Zafirlukast
• Others
By Route of Administration
• Oral
• Parenteral
• Nasal
• Others
By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Mylan N.V., Intersect ENT Inc, GlaxoSmithKline PLC, Lupin, Sanofi S.A, Sun Pharmaceutical Industries Ltd, Anant Pharmaceuticals Pvt. Ltd., OptiNose US, Teva Pharmaceutical Industries Ltd., Merck & Co Inc and among others.
Key Developments
• In August 6, 2020, for the treatment of adults (18 years and older) with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) for whom therapy with INC does not provide adequate disease control, Novartis stated that the European Commission (EC) had approved Xolair (omalizumab) as an add-on therapy with intranasal corticosteroids (INC).
Why Purchase the Report?
• To visualize the global nasal polyposis market segmentation based on disease type, drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of nasal polyposis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global nasal polyposis market report would provide approximately 69 tables, 69 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The rise of technological advancements
4.1.1.2. Increasing product approvals
4.2. Restraints
4.2.1.1. Expensive cost associated with the research and development
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Bilateral ethmoidal polyp *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Antrochoanal Polyp
8. By Drug Class
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.1.2. Market Attractiveness Index, By Drug Class
8.2. Nasal Corticosteroids *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Fluticasone
8.2.4. Mometasone
8.2.5. Budesonide
8.2.6. Beclomethasone
8.2.7. Others
8.3. Oral Corticosteroids
8.3.1. Prednisone
8.3.2. Prednisolone
8.4. Antihistamines
8.4.1. Cetirizine
8.4.2. Loratadine
8.4.3. Fexofenadine
8.4.4. Others
8.5. Leukotriene Modifiers
8.5.1. Montelukast
8.5.2. Zafirlukast
8.6. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
9.4. Nasal
9.5. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Mylan N.V. *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Intersect ENT Inc
13.3. GlaxoSmithKline PLC
13.4. Lupin
13.5. Sanofi S.A
13.6. Sun Pharmaceutical Industries Ltd
13.7. Anant Pharmaceuticals Pvt. Ltd.
13.8. OptiNose US
13.9. Teva Pharmaceutical Industries Ltd.
13.10. Merck & Co Inc
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Mylan N.V., 4.	Key Developments, Intersect ENT Inc, GlaxoSmithKline PLC, Lupin, Sanofi S.A, Sun Pharmaceutical Industries Ltd, Anant Pharmaceuticals Pvt. Ltd., OptiNose US, Teva Pharmaceutical Industries Ltd., Merck & Co Inc

표 목록 (Tables)

List of Tables

Table 1 Global Nasal Polyposis Drugs Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Nasal Polyposis Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Nasal Polyposis Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Nasal Polyposis Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Nasal Polyposis Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Nasal Polyposis Drugs Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Nasal Polyposis Drugs Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 8 Global Nasal Polyposis Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Nasal Polyposis Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 10 Global Nasal Polyposis Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Nasal Polyposis Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 12 Global Nasal Polyposis Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Nasal Polyposis Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 14 Global Nasal Polyposis Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Nasal Polyposis Drugs Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Nasal Polyposis Drugs Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 17 North America Nasal Polyposis Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 18 North America Nasal Polyposis Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 North America Nasal Polyposis Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 North America Nasal Polyposis Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Nasal Polyposis Drugs Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 22 South America Nasal Polyposis Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 23 South America Nasal Polyposis Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 24 South America Nasal Polyposis Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 25 South America Nasal Polyposis Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Nasal Polyposis Drugs Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 27 Europe Nasal Polyposis Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 28 Europe Nasal Polyposis Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 29 Europe Nasal Polyposis Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 Europe Nasal Polyposis Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Nasal Polyposis Drugs Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Nasal Polyposis Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Nasal Polyposis Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Nasal Polyposis Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Nasal Polyposis Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Nasal Polyposis Drugs Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Nasal Polyposis Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Nasal Polyposis Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Nasal Polyposis Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 40 Mylan N.V.: Overview

Table 41 Mylan N.V.: Product Portfolio

Table 42 Mylan N.V.: Key Developments

Table 43 Intersect ENT Inc: Overview

Table 44 Intersect ENT Inc: Product Portfolio

Table 45 Intersect ENT Inc: Key Developments

Table 46 GlaxoSmithKline PLC: Overview

Table 47 GlaxoSmithKline PLC: Product Portfolio

Table 48 GlaxoSmithKline PLC: Key Developments

Table 49 Lupin: Overview

Table 50 Lupin: Product Portfolio

Table 51 Lupin: Key Developments

Table 52 Sanofi S.A: Overview

Table 53 Sanofi S.A: Product Portfolio

Table 54 Sanofi S.A: Key Developments

Table 55 Sun Pharmaceutical Industries Ltd: Overview

Table 56 Sun Pharmaceutical Industries Ltd: Product Portfolio

Table 57 Sun Pharmaceutical Industries Ltd: Key Developments

Table 58 Anant Pharmaceuticals Pvt. Ltd.: Overview

Table 59 Anant Pharmaceuticals Pvt. Ltd.: Product Portfolio

Table 60 Anant Pharmaceuticals Pvt. Ltd.: Key Developments

Table 61 OptiNose US: Overview

Table 62 OptiNose US: Product Portfolio

Table 63 OptiNose US: Key Developments

Table 64 Teva Pharmaceutical Industries Ltd.: Overview

Table 65 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 66 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 67 Merck & Co Inc: Overview

Table 68 Merck & Co Inc: Product Portfolio

Table 69 Merck & Co Inc: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 2 Global Nasal Polyposis Drugs Market Share, By Disease Type, 2022 & 2030 (%)

Figure 3 Global Nasal Polyposis Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 4 Global Nasal Polyposis Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Nasal Polyposis Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Nasal Polyposis Drugs Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Nasal Polyposis Drugs Market Y-o-Y Growth, By Disease Type, 2022-2030 (%)

Figure 8 Bilateral ethmoidal polyp Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 9 Antrochoanal Polyp Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 10 Global Nasal Polyposis Drugs Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 11 Nasal Corticosteroids Drug Class in Global Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 12 Oral Corticosteroids Drug Class in Global Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 13 Antihistamines Drug Class in Global Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 14 Leukotriene Modifiers Drug Class in Global Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 15 Others Drug Class in Global Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 16 Global Nasal Polyposis Drugs Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 17 Oral Route of Administration in Global Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 18 Parenteral Route of Administration in Global Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 19 Nasal Route of Administration in Global Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 20 Others Route of Administration in Global Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 21 Global Nasal Polyposis Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 22 Hospital Pharmacies Distribution Channel in Global Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 23 Retail Pharmacies Distribution Channel in Global Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 24 Online Stores Distribution Channel in Global Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 25 Global Nasal Polyposis Drugs Market Y-o-Y Growths, By Region, 2022-2030 (%)

Figure 26 North America Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 27 Asia-Pacific Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 28 Europe Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 29 South America Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 30 Middle East and Africa Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 31 North America Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 32 North America Nasal Polyposis Drugs Market Share, By Disease Type, 2022 & 2030 (%)

Figure 33 North America Nasal Polyposis Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 34 North America Nasal Polyposis Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 35 North America Nasal Polyposis Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 36 North America Nasal Polyposis Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 37 South America Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 38 South America Nasal Polyposis Drugs Market Share, By Disease Type, 2022 & 2030 (%)

Figure 39 South America Nasal Polyposis Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 40 South America Nasal Polyposis Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 41 South America Nasal Polyposis Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 42 South America Nasal Polyposis Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 43 Europe Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 44 Europe Nasal Polyposis Drugs Market Share, By Disease Type, 2022 & 2030 (%)

Figure 45 Europe Nasal Polyposis Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 46 Europe Nasal Polyposis Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 47 Europe Nasal Polyposis Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 48 Europe Nasal Polyposis Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 49 Asia-Pacific Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 50 Asia-Pacific Nasal Polyposis Drugs Market Share, By Disease Type, 2022 & 2030 (%)

Figure 51 Asia-Pacific Nasal Polyposis Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 52 Asia-Pacific Nasal Polyposis Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 53 Asia-Pacific Nasal Polyposis Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 54 Asia-Pacific Nasal Polyposis Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 55 Middle East & Africa Nasal Polyposis Drugs Market Value, 2021-2030 (US$ Million)

Figure 56 Middle East & Africa Nasal Polyposis Drugs Market Share, By Disease Type, 2022 & 2030 (%)

Figure 57 Middle East & Africa Nasal Polyposis Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 58 Middle East & Africa Nasal Polyposis Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 59 Middle East & Africa Nasal Polyposis Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 60 Mylan N.V.: Financials

Figure 61 Intersect ENT Inc: Financials

Figure 62 GlaxoSmithKline PLC: Financials

Figure 63 Lupin: Financials

Figure 64 Sanofi S.A: Financials

Figure 65 Sun Pharmaceutical Industries Ltd: Financials

Figure 66 Anant Pharmaceuticals Pvt. Ltd.: Financials

Figure 67 OptiNose US: Financials

Figure 68 Teva Pharmaceutical Industries Ltd.: Financials

Figure 69 Merck & Co Inc: Financials

세계 비강 폴립증 시장 – 2023-2030

Global Nasal Polyposis Market - 2023-2030